Oslo, 11 May 2023. Lytix Biopharma - Lytix Biopharma AS ("Lytix") (Euronext
Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today releases
its first quarter 2023 results - New class of immunotherapy. 

"Lytix is fast approaching an important milestone, as we now are looking forward
to completing recruitment in our ATLAS-IT-05 study this summer and deliver the
first interim report from this study before the end of the year. At the same
time, we are encouraged by seeing our partner Verrica Pharmaceuticals continue
to make progress in their Phase II study, now running through the Part 2 of this
study in basal cell carcinoma patients after observing promising signs of
activity from Part 1 of the study.", says Dr. Øystein Rekdal, CEO of Lytix
Biopharma.


Highlights from the first quarter 2023:
o	ATLAS-IT-05
-	All six sites in Europe are now open and actively recruiting patients
-	One new site in the US opened during the quarter - UPMC Hillman Cancer Center 

o	Verrica Pharmaceuticals has completed treatment in part 1 of three parts of
their ongoing Phase II study evaluating LTX-315 in basal cell carcinoma
-	Part 1 has enrolled ten patients and demonstrated a favorable safety and
tolerability profile with no reported serious adverse events 
-	Patients receiving the higher range of dosing experienced a consistent
response of clinical tumor necrosis
o	Preparations for submission of Clinical Trial Application (CTA) required to
start a Phase I study with LTX-401 is ongoing
o	Lytix has delivered plenary lectures at two cancer immunotherapy conferences:
Immuno UK 2023 and Next-Gen Immuno-Oncology Conference

Key figures (unaudited) - see attachment.

***

The results will be presented in a webcast with CEO Øystein Rekdal, CDO Graeme
Currie and CFO Gjest Breistein today at 14.30 CEST. 

The presentation and subsequent Q&A session will be held in English and may be
viewed live by registering here: https://forms.office.com/e/BWzYZKqwjt
 
The presentation is available at www.lytixbiopharma.com in the Investors
section, and a recording of the presentation will after the presentation be made
available.


For more information, please contact: 
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com
Ole Peter Nordby, Head of IR & Communication Manager:
ole.peter.nordby@lytixbiopharma.com


Lytix in brief: 
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
Company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class oncolytic molecule representing a new
and superior in situ therapeutic vaccination principle to boost anti-cancer
immunity, with the potential to be the ideal combination partner with other
types of immunotherapy. LTX-315 target cancer cells and disintegrate their cell
membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens.  This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was listed on Euronext Growth
in Oslo in June 2021, following a private placement covered by investors such as
PBM Capital, a US based, healthcare-focused investment firm.